BofA upgraded Pharvaris (PHVS) to Neutral from Underperform with a price target of $27, up from $16.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PHVS:
- Pharvaris Secures Registration Rights Agreement with General Atlantic
- Pharvaris Advances Clinical Pipeline with Strong Financials
- Pharvaris’ Strategic Advancements and Financial Strength Bolster Buy Rating
- Pharvaris: Buy Rating Backed by Promising Trial Milestones and Strong Financial Position
- Pharvaris price target lowered to $52 from $55 at Citizens JMP